Alpha-1 research registry for diagnosed people and carriers
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This registry study enrolls people with Alpha-1 Antitrypsin Deficiency or certain genetic “carriers” to help researchers learn more about the condition. If you join, you may be asked to share health information over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Alpha-1 Antitrypsin Deficiency (like PiZZ, PiZNull, PiSZ).
- You may qualify as a genetic carrier (for example, PiMZ or PiMS).
- You must be able and willing to give informed consent.
- You cannot be a completely healthy person with the MM type.
- You should not be looking at this if you were told you are MM (normal) only.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects health information from people who have alpha-1 antitrypsin deficiency. It may help doctors better understand the condition and improve care over time.
This trial is a DNA and tissue sample registry for people interested in Alpha-1. It helps researchers study the condition by collecting samples for future research.
This study is looking at people with a specific mild form of alpha-1 antitrypsin deficiency (PiMZ) to understand how their lung disease progresses over time. It involves lung function tests and CT scans, and may help researchers learn more about the condition.
This study checks whether doing alpha-1 screening (genetic test and a blood level test) can help identify alpha-1 antitrypsin deficiency in people at risk. It may be useful if you have symptoms or a family history, but you haven’t had qualifying testing yet.
This study tests an experimental RNA-based medicine (AIR-001) for people with a genetic form of alpha-1 antitrypsin deficiency (AATD). It aims to see if the drug can help boost your body's own protective protein levels and may slow lung damage.
This trial tests a new treatment called BEAM-302, which aims to correct the genetic defect that causes alpha-1 antitrypsin deficiency. It may help prevent further lung and liver damage in people with the PiZZ mutation.
Hear when a new Alpha 1-Antitrypsin Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.